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A discussion of adventitious agents and vaccines is
pertinent in the context of emerging infectious diseases. Many
novel vaccines are produced in animal cell substrates, and
emerging infectious diseases may theoretically be transmit-
ted from animals to humans through these vaccines. The
challenge of identifying potential adventitious agents in
vaccines closely parallels the challenge of identifying the
agents causing particular emerging infectious diseases. Thus,
the major focus of this discussion will be the approaches used
in a regulatory setting to ensure that vaccines are devoid of
adventitious agents.
Maximal vaccine benefit is achieved when vaccination
rates are sufficiently high to achieve herd immunity. Because
vaccines are administered to healthy children, it is especially
important that parents, pediatricians, and the public at large
feel confident that the vaccines are safe. Knowing that
vaccines are free from adventitious agents is a large
component of this confidence. Thus, ensuring that vaccine
products that are administered to the public do not contain
adventitious agents is a regulatory goal. Of course, the
potential for the presence of adventitious agents in any
vaccine must also be evaluated in terms of the overall benefit
of the product.
In the past, biologic products have served as vectors for
viral diseases. Examples include the contamination of yellow
fever vaccine with hepatitis B virus in the 1940s (because a
human-derived excipient contained hepatitis B virus),
contamination of early polio and adenovirus vaccines with
simian virus 40 in the late 1950s and early 1960s,
contamination of blood products with hepatitis viruses and
HIV, and contamination of dura mater grafts with the
Creutzfeldt-Jakob disease agent. In these examples, either
human or animal materials used in production usually
caused the contamination.
Production of viral vaccines generally involves inocula-
tion of a cell substrate with a vaccine seed and purification of
bulk product from these cells after a sufficient time for
replication of the virus or production of vaccine proteins.
Other raw materials (e.g., tissue culture reagents, stabilizers)
may be added to the product at various stages of production.
Thus, adventitious agents could theoretically enter a viral
vaccine through any of these ingredients. Close control of the
vaccine manufacturing environment (by producing vaccines
in sophisticated modern facilities), appropriate testing of the
raw materials, and testing of both the bulk and final products
can help ensure that adventitious agents have not entered the
vaccine. Most vaccines are subjected to inactivation or
purification steps that can reduce the likelihood of
contamination with adventitious agents.
Current research on emerging infectious diseases may
help provide further assurance that new vaccines do not
contain adventitious agents. Powerful methods used to
discover viruses associated with emerging infectious diseases
are also being adapted to ensure that new vaccines (some of
which may be produced in novel cell substrates) are free of
adventitious agents.
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